Heart failure (HF) affects more than 15 million people in Europe and North America. Most of the studies performed in HF patients have been conducted in middle-aged adults. However, patients with HF are mainly elderly patients in whom management is complicated by comorbid conditions and the risk of adverse drug reactions. Little is known about the quality of care among this population. The aim of this prospective and multicenter study was to describe the in-hospital management in routine clinical settings of elderly patients over 75 years presenting to the emmergency department with pulmonary edema.

We used a global positioning satellite technology odometer to determine the maximum objective walking distance capacity (MOWD) of patients with multiple sclerosis (MS). The MOWD correlated with Expanded Disability Status Scale (EDSS) score (r 2 =0.41; P < 0.0001), the MSWS-12 scale (r 2 = 0.46; P < 0.0001), time to walk 10 m (r 2 = 0.51; P < 0.02) and walking speed (r 2 =0.75; P < 0.001). Limitation of walking capacities was measurable up to 4550 m, strikingly above the 500-m limit of the EDSS. This objective odometer is a promising tool for evaluation and follow-up of patients with MS. Multiple Sclerosis 2007; 13: 220–223. http://msj.sagepub.com

Background & Aims: Because most patients with focal nodular hyperplasia (FNH) are young women, an important decision is whether to discontinue oral contraceptive (OC) use. The aims of this study were to evaluate (1) the number and size of FNH lesions in women with various patterns of OC use and in women without OC use and (2) the modifications in the number and size of FNH lesions during follow-up, according to OC use, Methods: In a 9-year study in 216 women with FNH, the diameter and number of lesions documented by magnetic resonance (MR) imaging were evaluated (1) at diagnosis according to OC use as follows: group A, no OC use (n = 28); group B, high-dose OC use (n = 46); group C, low-dose OC use (n = 98); group D, successive use of high-dose and low-dose OCs (n = 33); and group E, use of progestogens only (n = 11); and (2) during follow-up in 136 women, 14 of whom were OC nonusers who stayed off OCs, 89 discontinued OC use, 26 took low-dose OCs, and 7 stayed on a progestogen only. Twelve women became pregnant. In 168 women, the diagnosis of FNH was made based on a combination of rigorously defined MR criteria. In the remaining 48 patients, diagnosis was by surgical biopsy (n = 36) or resection (n = 12). Mean diameter and number of lesion(s) per patient were assessed by MR imaging using the same protocol in all study patients. Results: No significant differences in the number or size of lesions were found in the 5 patient groups, During follow-up, a change in lesion diameter occurred in only 4 women; this event was not influenced by OC use, In the 12 patients who became pregnant, lesion size was unchanged after delivery, pregnancy was uneventful, and delivery occurred spontaneously. Conclusions: These data suggest that (1) neither the size nor the number of FNH lesions are influenced by OC use; (2) size changes during follow-up are rare and do not seem to depend on OC use; and (3) pregnancy is not associated with FNH changes or complications.

Fundamental & Clinical PharmacologyVolume 10, Issue 3 p. 319-320 Repeatability of laser Doppler measurements of cutaneous blood flow in clinical pharmacology studies P. Maison, P. Maison Service de Pharmacologie, Hôpital de Bicêtre, 78 rue du Général Leclerc, 94275 Le Kremlin Bicêtre, FranceSearch for more papers by this authorP. Démolis, P. Démolis Service de Pharmacologie, Hôpital de Bicêtre, 78 rue du Général Leclerc, 94275 Le Kremlin Bicêtre, FranceSearch for more papers by this authorJF Giudicelli, JF Giudicelli Service de Pharmacologie, Hôpital de Bicêtre, 78 rue du Général Leclerc, 94275 Le Kremlin Bicêtre, FranceSearch for more papers by this author P. Maison, P. Maison Service de Pharmacologie, Hôpital de Bicêtre, 78 rue du Général Leclerc, 94275 Le Kremlin Bicêtre, FranceSearch for more papers by this authorP. Démolis, P. Démolis Service de Pharmacologie, Hôpital de Bicêtre, 78 rue du Général Leclerc, 94275 Le Kremlin Bicêtre, FranceSearch for more papers by this authorJF Giudicelli, JF Giudicelli Service de Pharmacologie, Hôpital de Bicêtre, 78 rue du Général Leclerc, 94275 Le Kremlin Bicêtre, FranceSearch for more papers by this author First published: May‐June 1996 https://doi.org/10.1111/j.1472-8206.1996.tb00313.xCitations: 1AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL No abstract is available for this article.Citing Literature Volume10, Issue3May‐June 1996Pages 319-320 RelatedInformation

AbstractSharka caused by plum pox virus (PPV) is a disease spread in France since 1970, and causing severe damages essentially on apricot but also on plums and peach.Cherry is generally considered as not infected by PPV. Experimental transmissions by chip budding or aphids allowed to show that 3 isolates of PPV can multiply inside three cherry rootstocks (P. Mahaleb cv.‘SL 64′, P. avium cv.‘F 12‐1′, and P. avium*P. pseudocerasus cv. ‘Colt') (Tables 1 and 2).But generally, the virus remained localized to the infection site and disappeared quickly (Table 3). Typical symptoms of chlorotic ringspot or vein clearing are also limited to the leaves probed by the aphids.The fact that no translocation was detected is discussed.